MedTrace Logo

FOLFOXIRI With or Without Intensification for Rectal Cancer

NCT03997435 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2025-11-17

No results posted yet for this study

Summary

Pathologic complete response rate

Conditions

Interventions

DRUG

Control arm

neoadjuvant concurrent capecitabine-radiotherapy followed by surgery and postoperative chemotherapy.

DRUG

Experimental arm

Neoadjuvant FOLFOXIRI x4 cycles, then capecitabine-radiotherapy and postoperative chemotherapy.

Sponsors & Collaborators

  • CCTU

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-10
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03997435 on ClinicalTrials.gov